Clinical trials: Liver Inflammation
Chronic Hepatitis C
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
Data have suggested that consensus interferon (CIFN) has greater antiviral activity in vitro compared with interferon alfa-2a or alfa-2b.
- Trial name
- NCT00211692
- Testing
- consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin
- Volunteers
- 64 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Hepatitis C, Chronic
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin)…
- Trial name
- NCT01585324
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B Virus (HBV)
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT00734162
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- 21 sites in United States, Bulgaria and 5 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic, Hepatitis C
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
The objective of the study is to evaluate, in each group, the number of participants who achieve rapid virological response (RVR) after 4 weeks treatment with PegIntron and Rebetol.
- Trial name
- APEGIN (NCT00724854)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 1,146 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (PegIntron®/peg-IFN) and ribavirin (RBV) in chronic hepatitis C (CHC) Genotype I…
- Trial name
- NCT01405937
- Testing
- vaniprevir, peg-IFN, ribavirin
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.
- Trial name
- FOURward (NCT02175966)
- Testing
- DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment
The purpose of this study is to determine the efficacy, safety and tolerability of different regimens of TMC435 with standard treatment compared to standard treatment alone in participants with chronic, genotype 1, hepatitis C…
- Trial name
- ASPIRE (NCT00980330)
- Testing
- TMC435, Peg-IFN-alfa-2a (P), Ribavirin (R)
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 463 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis B
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.
- Trial name
- NCT05770895
- Testing
- GS-2829, GS-6779
- Where
- 9 sites in New Zealand, Taiwan
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C
Staged Phase I/II Hepatitis C Prophylactic Vaccine
A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45.
- Trial name
- NCT01436357
- Testing
- AdCh3NSmut1, MVA-NSmut
- Where
- 5 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
The predominant remaining questions for post-transplant treatment of Hepatitis C virus (HCV) in the DAA (direct acting anti-virals) era are whether a ribavirin-free regimen is possible and whether pre-emptive treatment is now a…
- Trial name
- NCT02631772
- Testing
- Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Medical University of South Carolina
Chronic Hepatitis C Infection
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
The purpose of this study is to study the effects of valacyclovir on patients who have hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which causes genital herpes.
- Trial name
- NCT01453075
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Alcohol Use Disorder, HIV/AIDS
Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV
Among patients with HIV, especially those also infected with HCV, heavy drinking is associated with significant risks to health.
- Conditions
- Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
- Trial name
- NCT03652675
- Testing
- Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- New York State Psychiatric Institute
Hepatitis C Virus
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of ABT-450/r/ABT-267 co-administered with weight-based…
- Trial name
- GIFT-II (NCT02023112)
- Testing
- ABT-450/r/ABT-267, Ribavirin
- Volunteers
- 171 people
- Sponsor
- AbbVie
Chronic Hepatitis C (CHC)
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in patients with genotype 1 hepatitis C, who are naïve to its treatment or relapsed after previous treatment.
- Trial name
- NCT01753557
- Testing
- MP-424, RBV, PEG-IFN alfa-2a
- Where
- Japan
- Volunteers
- 54 people
- Sponsor
- Tanabe Pharma Corporation
HIV Infections
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
The purpose of this study is to determine whether daily use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV counseling, condoms, and treatment for other sexually…
- Trial name
- iPrEx (NCT00458393)
- Testing
- daily TDF/FTC
- Where
- 11 sites in United States, Brazil and 4 more
- Volunteers
- 2,499 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
Chronic HBV Management for Asian American
About 75% of liver cancers are attributed to chronic hepatitis B (CHB). An estimated 2.2 million individuals in the U.S. have CHB. Although Asian Americans make up 6% of total U.S.
- Trial name
- NCT04082338
- Testing
- VPN, TM
- Where
- 2 sites in United States
- Volunteers
- 382 people
- Sponsor
- Temple University
Hepatitis B, Chronic, Cirrhosis
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
This 36-month open-label study of adefovir dipivoxil investigates the clinical benefits of the therapy in chronic hepatitis B patients with advanced fibrosis or cirrhosis confirmed with biopsy.
- Conditions
- Hepatitis B, Chronic, Cirrhosis, Fibrosis, Chronic Hepatitis B
- Trial name
- NCT00347009
- Testing
- adefovir dipivoxil
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 155 people
- Sponsor
- GlaxoSmithKline
Whole Cell Pertussis, Haemophilus Influenzae Type b
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of DTPw-HBV/Hib-MenAC compared to DTPw-HBV/Hib given to healthy subjects at 15 to 24 months of age primed with 3 doses of…
- Conditions
- Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B, Diphtheria
- Trial name
- NCT00136604
- Testing
- Tritanrix-HepB/Hib-MenAC, Mencevax ACWY, Tritanrix-HepB/Hiberix
- Where
- 3 sites in Thailand
- Volunteers
- 617 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Liver Diseases, Hypertension, Portal
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this study if they have high blood pressure in the portal vein (main vessel going to the…
- Trial name
- NCT05282121
- Testing
- Avenciguat, Empagliflozin
- Where
- 31 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Liver Disease, Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Background: Infection with hepatitis D virus leads to a chronic liver disease with no effective treatment. Lonafarnib has improved hepatitis D virus levels in blood, but the medication still needs more research.
- Trial name
- NCT03600714
- Testing
- Peg-interferon lambda, Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.